Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer

Cancer Research

Volumn 67, Issue 10, 2007, Pages 5033-5041

  Mostaghel, Elahe A ^a   Page, Stephanie T ^a,b   Lin, Daniel W ^a,b   Fazli, Ladan ^c   Coleman, Ilsa M ^a   True, Lawrence D ^a   Knudsen, Beatrice ^a   Hess, David L ^d   Nelson, Colleen C ^c   Matsumoto, Alvin M ^a,b   Bremner, William J ^a   Gleave, Martin E ^c   Nelson, Peter S ^a,e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLINE; ANDROGEN; ANDROGEN RECEPTOR; GONADORELIN ANTAGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CASTRATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENETIC REGULATION; HORMONE ACTION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; ANDROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGOPEPTIDES; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TESTOSTERONE;

EID: 34250331066     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3332     Document Type: Article

References (49)

1. Geller J, Liu J, Albert J, Fay W, Berry CC, Weis P. Relationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone level. Clin Endocrinol (Oxf) 1987;26:155-61.
2. Forti G, Salerno R, Moneti G, et al. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5α-reductase activity and androgen receptor content. J Clin Endocrinol Metab 1989;68:461-8.
3. Mohler JL, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8.
4. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004;10:7121-6.
5. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006; 91:3850-6.
6. Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999;81:242-51.
7. Gregory CW, Johnson RT, Jr., Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-8.
8. Gregory CW, Hamil KG, Kim D, et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998;58:5718-24.
9. Mohler JL, Morris TL, Ford OH III, Alvey RF, Sakamoto C, Gregory CW. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate 2002;51:247-55.
10. Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab 2004;89: 5959-65.
11. Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004;64:6595-602.
12. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002;50:179-88.
13. Marks LS, Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, Tyler VE. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001;57: 999-1005.
14. Resko JA, Ellinwood WE, Pasztor LM, Huhl AE. Sex steroids in the umbilical circulation of fetal rhesus monkeys from the time of gonadal differentiation. J Clin Endocrinol Metab 1980;50:900-5.
15. Ruijter E, van de Kaa C, Aalders T, et al.; BIOMED-II Markers for Prostate Cancer Study Group. Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. Mod Pathol 1998;11:276-81.
16. De Marzo AM, Platz EA, Epstein JI, et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006;30:1281-91.
17. Nelson PS, Pritchard C, Abbott D, Clegg N. The human (PEDB) and mouse (mPEDB) Prostate Expression Databases. Nucleic Acids Res 2002;30:218-20.
18. Pritchard CC, Hsu L, Delrow J, Nelson PS. Project normal: defining normal variance in mouse gene expression. Proc Natl Acad Sci USA 2001;98:13266-71.
19. True L, Coleman I, Hawley S, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006;103: 10991-6.
20. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
21. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
22. Nelson PS, Clegg N, Arnold H, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 2002;99:11890-5.
23. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000;60: 170-6.
24. Weir EG, Partin AW, Epstein JI. Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol 2000;163:1739-42.
25. Paterson RF, Gleave ME, Jones EC, Zubovits JT, Goldenberg SL, Sullivan LD. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormonal therapy. Mol Urol 1999;3:277-86.
26. Krieg M, Nass R, Tunn S. Effect of aging on endogenous level of 5α-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993;77:375-81.
27. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing -hormone -releasing-hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987;317: 559-604.
28. Ohlson N, Wikstrom P, Stattin P, Bergh A. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 2005;62:307-15.
29. Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol 2005;173:1772-7.
30. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 2005;5:45.
31. Holzbeierlein J, Lai P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164:217-27.
32. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11:459-76.
33. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997;15:382-8.
34. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004; 171:679-83.
35. Shibata Y, Ono Y, Kashiwagi B, et al. Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate. Urology 2003;62: 942-6.
36. Shibata Y, Kashiwagi B, Arai S, et al. Direct regulation of prostate blood flow by vascular endothelial growth factor and its participation in the androgenic regulation of prostate blood flow in vivo. Endocrinology 2004;145: 4507-12.
37. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65.
38. Stege RH, Tribukait B, Carlstrom KA, Grande M, Pousette AH. Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy. Prostate 1999; 38:183-8.
39. Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59:803-6.
40. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-9.
41. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
42. Mizokami A, Koh E, Fujita H, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64:765-71.
43. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002;277:7076-85.
44. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
45. Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 2003;23:104-18.
46. Koh E, Noda T, Kanaya J, Namiki M. Differential expression of 17β-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 2002;53:154-9.
47. Harkonen P, Torn S, Kurkela R, et al. Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state. J Clin Endocrinol Metab 2003;88:705-12.
48. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63:231-9.
49. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.